Al Robichaud

Al Robichaud

Private Equity Investor at
Cure Ventures Management LP
65 year
Consumer Services
Health Technology
Commercial Services

Profile

Currently, Albert J. Robichaud is Chief Scientific Officer of SAGE Therapeutics, Inc. Dr. Robichaud previously held the position of VP-Chemistry & Pharmacokinetic Sciences at Lundbeck USA Inc., VP-Chemistry & Pharmacokinetic Sciences at Lundbeck, Inc. and Senior Director & Head-Neuroscience Discovery at Wyeth Research. Albert J. Robichaud received an undergraduate degree from Rensselaer Polytechnic Institute and a doctorate from the University of California, Irvine.

Al Robichaud active positions

CompaniesPositionStart
Private Equity Investor 2023-12-31

Former positions of Al Robichaud

CompaniesPositionEnd
SAGE THERAPEUTICS, INC. Chief Tech/Sci/R&D Officer 2023-10-08
Corporate Officer/Principal 2010-12-31
Director/Board Member 2009-12-31
Lundbeck USA Inc.
Corporate Officer/Principal -
See the detail of Al Robichaud's experience

Training of Al Robichaud

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

32

1st degree connections

7

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies7

Consumer Services

Consumer Services

Commercial Services

Health Technology

Lundbeck USA Inc.

Health Technology

Finance